Hong Kong-listed Sihuan Pharmaceutical said it has joined hands with U.S.-based Covance to develop a drug pipeline aimed at China and U.S. approvals.
Infinity Pharmaceuticals exercised an option this week to purchase worldwide royalty obligations ranging from 7% to 11% on sales of duvelisib (IPI-145) in oncology indications from Takeda Pharmaceutical for $52.5 million.
Nasdaq-listed Neurocrine Biosciences signed an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma. The deal may lead to as much as $85 million in payments with milestones met.
An Investigational New Drug application for WuXi PharmaTech and MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis was accepted for review by the China Food and Drug Administration, the company said this week, marking a milestone in a development partnership started less than three years ago.
23andMe is making its first foray into retail, teaming up with U.K. health and beauty company Superdrug to sell its genetic tests in the country.
Months after LabCorp acquired its rival Covance, Quintiles has signed a sweeping agreement with lab testing giant Quest Diagnostics to launch a joint venture focused on clinical trials.
Germany's Bayer already partners with MIT and Harvard on oncology research, and now the partnership is being upgraded to include cardiovascular genomics and drug discovery. The expansion of the alliance into cardiovascular genomics will be about the search for genetic biomarkers of patient risk or suitability to particular drugs that treat cardiovascular conditions like heart disease.
Quest Diagnostics is forming a joint venture with global CRO Quintiles to provide laboratory services for clinical trials, lending its research and diagnostic know-how to biopharma partners with precision medicine initiatives.
Quest Diagnostics is partnering with contract research organization Quintiles to create a joint venture to provide a range of clinical trial services to biopharmas including laboratory testing and patient recruitment and retention as well as development and commercialization of companion diagnostics.
Under the guidance of drug delivery guru Dr. Robert Langer of MIT and Massachusetts General Hospital's Dr. William Crowley, Boston's Columbia Laboratories has acquired the license to an intravaginal ring designed to deliver several different drugs at a time.